Advertisement

Annals of Nuclear Medicine

, Volume 20, Issue 1, pp 63–67 | Cite as

Differentiated thyroid cancer: comparison of therapeutic iodine 131 biological elimination after discontinuation of levothyroxine versus administration of recombinant human thyrotropin

  • Dimitris Papadimitriou
  • Sofia Kottou
  • Loukia Oros
  • Ioannis Ilias
  • Michael Molfetas
  • Virginia Tsapaki
  • Antonis Perris
  • Ioulia Christakopoulou
Original Article

Abstract

The biological elimination of therapeutic131I in patients with differentiated thyroid cancer (DTC), post total or near-total thyroidectomy, was compared after withholding levothyroxine suppression against administration of recombinant human thyrotropin without stopping levothyroxine. In 163 patients (group G1) levothyroxine was withheld before131I therapy: in 138 patients the tumor was limited to the thyroid bed (group G1.1) and in 25 patients metastases were present (group G1.2). A second group of patients (G2; n = 28) received131I therapy after administration of recombinant human thyrotropin without stopping levothyroxine. Mean retained131I activity (as a percentage of the administered dose) was 5%-29% (group G1.1), 20%-43% (group G1.2) and 1 %-17% (group G2). The effective half-life of131I was 0.59-0.69 days (group G1.1), 0.87-1.22 days (group G1.2) and 0.38-0.44 days (group G2). In conclusion, the use of recombinant human thyrotropin to prepare patients with thyroid cancer for therapy with131I shortens its effective half-life and reduces its retained activity compared to preparation with discontinuation of levothyroxine suppression.

Key words

131thyroid cancer retained activity effective half-life 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    NRC. U.S. Nuclear Regulatory Commission 1997 Criteria for the release of individuals administered radioactive materials-NRC, Final rule.Fed Regist 1997; 62: 4120–4133.Google Scholar
  2. 2.
    ICRP. International Commission on Radiological Protection Radiation Dose to Patients from Radiopharmaceuticals, ICRP Publication No. 53. Elmsford, NY; Pergamon Press, 1987.Google Scholar
  3. 3.
    Papadimitriou D, Oros L, Manetou A, Perris A, Molfetas M, Kottou S. Exposure rates (versus time after administration) in relation with clinical factors for thyroid carcinoma patients treated with iodine-131. European IRPA Congress 2002. Florence, Italy, October 8–11, 2002.Google Scholar
  4. 4.
    Serafini A, Clauss R, Levis-Dusseau S. tProtocol for the combined diagnostic and therapeutic use of recombinant human thyroid—stimulating hormone.Clin Nucl Med 2003;28: 14–17.PubMedCrossRefGoogle Scholar
  5. 5.
    Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A, et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on I-thyroxine, using recombinant human TSH.Eur J Endocrinol 2001;144:5–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Luster M, Lassman M, Haenscheid H, Michalowski U, Incerti C, Reiners C. tUse of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.J Clin Endocrinol Metab 2000;85: 3640–3645.PubMedCrossRefGoogle Scholar
  7. 7.
    Vitale G, Lupoli GA, Ciccarelli A, Fonderico F, Klain M, Squame G, et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre.Clin Endocrinol 2002; 56: 247–252.CrossRefGoogle Scholar
  8. 8.
    Emerson CH, Torres MS. Recombinant human thyroid-stimulating hormone: pharmacology, clinical applications and potential uses.BioDrugs 2003; 17: 19–38.PubMedCrossRefGoogle Scholar
  9. 9.
    Schlumberger MJ, Incerti C, Pacini F, Reiners C. tThe role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion.J Endocrinol Invest 1999; 22 (11 suppl): 35–41.PubMedGoogle Scholar
  10. 10.
    Dow KH, Ferrell BR, Anello C. tQuality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy.Thyroid 1977; 7: 613–619.CrossRefGoogle Scholar
  11. 11.
    Klein I, Ojamaa K. tThyroid hormone and the cardiovascular system.N Engl J Med 2001; 344: 501–509.PubMedCrossRefGoogle Scholar
  12. 12.
    Euratom Commission Radiation Protection. Radiation protection following iodine-131 therapy. Exposures due to outpatients or discharged inpatients. Luxemburg; Directorate General, Environment, Nuclear Safety and Clinical Protection, 1998.Google Scholar
  13. 13.
    Schlumberger M, Pacini F.Differentiated thyroid carcinoma. Paris; Nucleon, 1999: 85–105.Google Scholar
  14. 14.
    Stabin MG, Watson EE, Marcus CS, Salk RD. Radiation Dosimetry for the Adult Female and Fetus from Iodine-131 Administration in Hyperthyroidism.J Nucl Med 1991; 32:808–813.PubMedGoogle Scholar
  15. 15.
    Venencia CD, Germanier AG, Bustos SR, Giovannini AA, Wyse EP. Hospital discharge of patients with thyroid carcinoma treated with131l.J Nucl Med 2002; 43: 61–65.PubMedGoogle Scholar
  16. 16.
    North DL, Shearer DR, Hennessey JV, Donovan GL. Effective half-life of131I in thyroid cancer patients.Health Phys 2001;81:325–329.PubMedCrossRefGoogle Scholar
  17. 17.
    Hennessey J, Kreisman S. tConsistent reversible elevations of serum Creatinine levels in severe hypothyroidism.Arch Intern Med 1999; 159: 79–82.PubMedCrossRefGoogle Scholar
  18. 18.
    De Keizer B, Barns B, Hoekstra A, Zelissen P, Koppeschaar H, Lips C, et al. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy.Eur J Nucl Med Molecular Imaging 2003; 30: 367–373.Google Scholar
  19. 19.
    Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer.N Engl J Med 1983; 309: 937–941.PubMedGoogle Scholar
  20. 20.
    Park SG, Reynolds JC, Brucker-Davis F. tIodine kinetics during 1-131 scanning in patients with thyroid cancer: comparison of studies with recombinant human TSH (rhTSH) vs hypothyroidism.J Nucl Med 1996; 37 (suppl 1):15.Google Scholar
  21. 21.
    Goslings BM. Effect of a low iodine diet on 131-1 therapy in follicular thyroid carcinomata.J Endocrinol 1975; 64:30P.PubMedGoogle Scholar
  22. 22.
    Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.Endocr Relat Cancer 2005; 12: 49–64.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  • Dimitris Papadimitriou
    • 1
  • Sofia Kottou
    • 2
  • Loukia Oros
    • 1
  • Ioannis Ilias
    • 3
  • Michael Molfetas
    • 4
  • Virginia Tsapaki
    • 5
  • Antonis Perris
    • 6
  • Ioulia Christakopoulou
    • 7
  1. 1.Department of Nuclear MedicineWhite Cross General HospitalPiraeusGreece
  2. 2.Department of Medical Physics, Medical SchoolUniversity of AthensAthensGreece
  3. 3.Department of Pharmacology, Medical SchoolUniversity of PatrasRion-PatrasGreece
  4. 4.Department of Medical PhysicsEvagelismos HospitalAthensGreece
  5. 5.Department of Medical PhysicsKonstantopoulio-Agia Olga HospitalAthensGreece
  6. 6.Department of Radiology, Aretaieion HospitalUniversity of AthensAthensGreece
  7. 7.Department of Nuclear MedicineSotiria General HospitalAthensGreece

Personalised recommendations